Eculizumab for pregnancy-related atypical hemolytic uremic syndrome

Korotchaeva Yulia Vyacheslavovna ^{1, 2} , Kozlovskaya N.L. ^{2, 3} , Shifman Efim Munevich ⁴ , Kudlay Dmitry Anatolievich ¹ , Moiseev Sergey V. ¹

Oxford University Press

10

English

1731-1733

Published

39

2024

cephalosporin; creatinine; cyclophosphamide; eculizumab; hemoglobin; lactate dehydrogenase; monoclonal antibody; quinolone derivative; complement inhibitor; acute heart failure; acute kidney failure; adult; adult respiratory distress syndrome; all cause mortality; anuria; Article; atypical hemolytic uraemic syndrome; bleeding; blood brain barrier; cerebrovascular accident; chronic kidney failure; coma; complement inhibition; controlled study; dialysis; end stage renal disease; endothelium lesion; female; follow up; heart infarction; hemodialysis; human; liver injury; major clinical study; microangiopathic hemolytic anemia; microangiopathy; microvascular thrombosis; morbidity; mortality; platelet count; preeclampsia; pregnancy; renal replacement therapy; seizure; systemic thrombotic microangiopathy; tertiary care center; thrombocytopenia; thrombotic microangiopathy; thrombotic thrombocytopenic purpura; vascular microthrombosis; case report; drug therapy; pregnancy complication; Antibodies, Monoclonal, Humanized; Atypical Hemolytic Uremic Syndrome; Complement Inactivating Agents; Humans; Pregnancy Complications